The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Procept BioRobotics shares soared 30% on Wednesday after the company said its robotic system designed to treat benign prostatic hyperplasia received clearance from the Food and Drug Administration ...
PROCEPT BioRobotics (NASDAQ:PRCT) is preparing to release its quarterly earnings on Tuesday, 2026-02-24. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...
Okay. I think we're ready to get started. Thanks, everyone. I'm Dave Rescott, senior med tech analyst here at Baird. Happy to have the PROCEPT team here with ...
Waters stated, “We now expect full year 2025 total revenue to be approximately $325.5 million, representing growth of approximately 45% compared to 2024.” System sales guidance for the U.S. remains at ...
META: $214.48 million (5.3% of AUM) GOOGL: $171.23 million (4.2% of AUM) AMZN: $161.25 million (4.0% of AUM) NVDA: $149.51 million (3.7% of AUM) V: $137.50 million (3.4% of AUM) As of October 21, 2025 ...
Shares of PROCEPT BioRobotics (PRCT) fell 8% on Thursday after Leerink Partners downgraded the stock to Market Perform from Outperform and lowered its price target to $29 from $31, citing growing ...
On Thursday, Spruce Point Capital released a detailed report on PROCEPT BioRobotics (NASDAQ:PRCT), raising concerns about the claims surrounding its market potential and growth prospects, suggesting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results